Identical twin toddlers who presented with severe arthritis helped scientists to identify the first gene mutation that can single-handedly cause a juvenile form of this inflammatory joint disease. By investigating the DNA of individual blood cells of both children and then modelling the genetic defect in a mouse model, the research team led by Adrian Liston (VIB-KU Leuven) was able to unravel the disease mechanism. The findings may help to develop an appropriate treatment as well.
Juvenile idiopathic arthritis is the most common form of all childhood rheumatic diseases. It is defined as arthritis that starts at a young age and persists throughout adulthood, but which does not have a defined cause. Patients present with a highly variable clinical picture, and scientists have long suspected that different combinations of specific genetic susceptibilities and environmental triggers drive the disease.
A single gene mutation
In a new study by researchers at VIB, KU Leuven and UZ Leuven, the cause of juvenile arthritis in a young pair of identical twins was traced back to a single genetic mutation.
“Single-cell sequencing let us track what was going wrong in every cell type in the twin’s blood, creating a link from genetic mutation to disease onset,” explains Dr. Stephanie Humblet-Baron (VIB-KU Leuven), one of the researchers involved in the study. “It was the combination of next generation genetics and immunology approaches that allowed us to find out why these patients were developing arthritis at such a young age.”
Modelling a human disease in mice
Parallel studies in mice confirmed that the gene defect found in the patients’ blood cells indeed led to an enhanced susceptibility to arthritis. Prof. Susan Schlenner (VIB-KU Leuven), first author of the study, stresses the relevance of this approach: “New genetic editing approaches bring mouse research much closer to the patient. We can now rapidly produce new mouse models that reproduce human mutations in mice, allowing us to model the disease of individual patients.”
According to immunology prof. Adrian Liston (VIB-KU Leuven) such insights prove invaluable in biomedical research: “Understanding the cause of the disease unlocks the key to treating the patient.”
From cause to cure
Liston’s team collaborated closely with prof. Carine Wouters (UZ Leuven), who coordinated the clinical aspect of the research: “The identification of a single gene that can cause juvenile idiopathic arthritis is an important milestone. A parallel mouse model with the same genetic mutation is a great tool to dissect the disease mechanism in more detail and to develop more effective targeted therapies for this condition.”
And the young patients? They are relieved to know that scientists found the cause of their symptoms: “We are delighted to know that an explanation has been found for our illness and more so because we are sure it will help other children.”
Thankfully, the youngsters’ arthritis is under good control at th?e moment. Thanks to the new scientific findings, their doctors will be in a much better position to treat any future flare-ups.
The Latest on: Juvenile idiopathic arthritis
via Google News
The Latest on: Juvenile idiopathic arthritis
- Rheumatologists: On the COVID-19 Front Lineon March 22, 2020 at 11:03 am
Fatalities are not uncommon. Patients with certain rheumatic diseases, particularly those with systemic juvenile idiopathic arthritis or adult-onset Still's disease, are most often affected by those ...
- Roche to Evaluate Actemra for Severe COVID-19 Pneumoniaon March 19, 2020 at 11:38 pm
works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.
- Genentech arthritis drug to be tested against COVID-19on March 19, 2020 at 12:19 pm
Biotech giant Genentech Inc. is working with federal agencies to start a late-stage clinical trial in early April of its already-approved rheumatoid arthritis drug Actemra against the virus that ...
- The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNAon March 18, 2020 at 9:30 am
Chicago, IL – March 18, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and ...
- Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infectionon March 17, 2020 at 12:47 pm
A U.S. based phase II/III study has been initiated to evaluate Regeneron (REGN)/Sanofi's (SNY) rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19.
- Adalimumab trials show low rate of IBD adverse eventson March 16, 2020 at 1:39 pm
According to the researchers, these trials included 24,114 patients with various conditions, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, pediatric enthesitisrelated ...
- Anakinra effective in pediatric secondary hemophagocytic lymphohistiocytosison March 11, 2020 at 1:48 pm
“While the safety and benefits of IL1 blockade in the inflammatory process have been demonstrated in many diseases, including in the treatment of systemic juvenile idiopathic arthritis (JIA) and ...
- The misconception that arthritis only affects the elderlyon March 8, 2020 at 11:05 pm
With its high prevalence, there is a common misconception that arthritis is a condition that only affects the elderly and adults. This isn’t the case though. Juvenile idiopathic arthritis (JIA) can ...
- Teenager with rare juvenile arthritis 'feels trapped' in the body of an 80-year-oldon March 7, 2020 at 11:03 pm
thanks to a rare form of juvenile arthritis According to YorkshireLive, the 16-year-old is constantly in pain from juvenile idiopathic arthritis (JIA), so bad that she has considered undergoing ...
- Joint Replacement for Juvenile Idiopathic Arthritison March 2, 2020 at 4:00 pm
But kids with juvenile idiopathic arthritis (JIA), who have painful, stiff joints, might get relief, too. When medicine and other treatments haven't worked, joint replacement can offer dramatic ...
via Bing News